A double blind trial was conducted to determine the dose of ibuprofen suspension, which is effective in reducing the body temperature. The principal measure of efficacy was a reduction in axillary temperature of PC or more three hours after dosing. A second objective of the trial was to compare the incidence and severity of side effects and the palatability of a range of ibuprofen doses.
Fever is one of the commonest features of illness in children, leads to many hospital admissions, and engenders a great deal of parental anxiety. It remains controversial whether fever causes or is simply associated with febrile convulsions,' but much time and effort are spent in reducing the temperature of these children and there is reluctance to discharge such children until they are apyrexial.
With the recognition that aspirin in febrile children is associated with an increased incidence of Reye's syndrome,2 paracetamol became the only antipyretic agent used routinely in children. If a more potent antipyretic, which was as safe or safer than paracetamol, was available then this would be a valuable addition to the paediatric formulary. If such a drug also had powerful anti-inflammatory and analgesic actions, other symptoms often associated with fever would also be alleviated.
Ibuprofen is a propionic acid derivative that has been used to relieve inflammation and pain for over 20 years and has been available for the treatment of juvenile rheumatoid arthritis since 1979. Although it has also been known for some time that ibuprofen has powerful antipyretic effects in both animal models3 4 and children,5 this non-steroidal anti-inflammatory drug has not had a UK product licence for this purpose in children until 1990 .
There have been a number of trials that have compared the antipyretic properties of ibuprofen with paracetamol in children58 and this was not the purpose of this present study. It has been established by these trials that ibuprofen compares favourably with paracetamol but the minimum ibuprofen dose that is effective and the comparative tolerance over a range of doses have not been established. We present the results of a double blind trial, the main aim of which was to determine the minimum dose of oral ibuprofen suspension that is effective in reducing fever in children. A second objective was to compare the incidence and severity of side effects of a range of doses.
Patients and methods
The trial was conducted at the University Hospital, Nottingham, and had the approval of the Nottingham Hospitals ethics committee. Written, informed consent was obtained from a parent or guardian.
In recognition of the difficulties in defmiing the normal body temperature range of children at different times of day and in different thermal environments, the principal index of antipyretic efficacy chosen was a reduction in body temperature of 1°C or more within three hours of the dose rather than an absolute body temperature. This criterion was defined before the study.
Children of either sex were eligible provided that the axillary temperature on admission to the ward was 37.5°C or more. A body weight less than 8 kg precluded entry to the trial and no child was studied twice. Children were also ineligible if there were relative contraindications to oral non-steroidal anti-inflammatory drugs (bleeding disorder; hepatic, renal or cardiac disease; peptic ulceration; recurrent severe bronchospasm; receiving immunosuppressant treatment, bronchodilators, digoxin or diuretics; previous adverse reaction to aspirin or nonsteroidal anti-inflammatory drugs). Children were not excluded if they had received previous antipyretics, antibiotics, or other concomitant drug treatment. Entry to the trial was immediately after the eligibility assessment except when paracetamol or aspirin had been given in the previous four hours in which case these drugs were discontinued and a washout period of four hours was allowed. There were no children taking non-steroidal anti-inflammatory drugs at the time of entry to the trial. Randomisation to treatment was arranged so that equal numbers of patients were allocated to receive one of four strengths of ibuprofen suspension: 2-5 mg/ml, 5 mg/ml, 10 mg/ml, or 20 mg/ml. An appropriate volume of suspension of one of these strengths was given, depending on body weight, such that the children were effectively randomly allocated to receive one of four doses of ibuprofen suspension: 0-625 mg/kg, 1-25 mg/kg, 2-5 mg/kg, or 5-0 mg/kg. The four study medications were identical opaque orange syrups and similar in taste. Medications were administered using a plastic measuring cylinder and 5 ml of water used to rinse any residual volume of medication from the dispenser. The randomised dose to which the child was allocated was repeated six hours after the initial dose.
It was considered unethical to include a placebo control group. To meet the concern that the weaker ibuprofen regimens might piove ineffective a supplementary medication was provided by ibuprofen 2-5 mg/kg (10 mg/ml strength of suspension). In the event that the axillary temperature remained above 37-2°C three hours after the initial randomised dose of ibuprofen, a 'rescue' dose of supplementary medication could be administered. If the child was given this 'rescue' dose, no medication was given at six hours after the initial randomised dose but the child received a second dose of the supplementary medication at nine hours.
The demographic data collected on entry to the trial consisted of age, sex, body weight, and concomitant treatment. The axillary temperatures of the children were recorded using a digital thermometer (Comark Products International) immediately before the initial dose (baseline) and at 0 25, 0 5, 1, 2, 3, 4, 6, 9, and 12 hours after the initial randomised dose of ibuprofen. These measurements were very reproducible (within observer variation ±0-1°C). The clinical condition of the child was evaluated 3, 6, and 12 hours after the initial dose by one 'blind' investigator (SCM) on a five point scale with categories much worse, worse, no change, improved, and much improved. The acceptability of the medication to the child was assessed by the same investigator on a five point scale (very acceptable, acceptable, indifferent, unacceptable, very unacceptable) at the initial and repeat dosings.
All adverse clinical events that occurred during the 12 hour period of the trial were recorded irrespective of whether or not these events were considered to be a side effect of ibuprofen. The case notes of children for whom an adverse event was recorded were subsequently reviewed by one of us (DH), who remained 'blind' to which dose of ibuprofen the children had been randomised and who made an assessment of whether the adverse event was part of the natural history of the child's condition or a side effect of ibuprofen.
STATISTICAL ANALYSIS
The effect of different doses on the number of patients withdrawing were compared using the x2 test. The change in temperature at three hours from baseline was analysed for each dose of ibuprofen using the paired t test and 95% confidence intervals were calculated for the mean differences between baseline axillary temperature and the temperature at three hours. Differ'ences between doses in the temperature at three hours, the clinical condition at three hours, and the acceptability of the medication were tested by analysis of covariance, using age and baseline temperature as the covariates. Differences between doses in the number of children who warranted supplementary medication were compared using the x2 test. The effects of different doses on the number of children suffering adverse clinical events were compared using the x2 test.
Results
One hundred children were recruited into the study. Seven of the children who had been entered did not, in retrospect, fulfil the eligibil-' ity criteria. The 93 remaining children (57 boys and 36 girls) were included in the analysis. Their mean (SD) age was 2-6 (1-7) years, mean body weight 13-1 (4-2) kg, and mean baseline axillary temperature 38-6 (0-7)°C. Twenty two (24%) of these children were already receiving some medication when recruited to the study. The four treatment groups showed no significant differences in age, weight, baseline, axillary temperature, or frequency of concomitant treatment (table 1) .
WITHDRAWALS FROM THE TRIAL
Of the 93 eligible children who received a first randomised dose of ibuprofen, 18 children were withdrawn from the trial by the clinical investigator before the 12 hour study period was completed. The reasons were lack of response, as judged by an axillary temperature persisting above 37 2°C despite a 'supplementary' dose of ibuprofen at three hours (n=13) or an adverse event (n= 5). In addition, one child made a complete recovery and was discharged from hospital before completion of the 12 hour period, and there were incomplete data for a further four children. In total, therefore, the data set analysed was incomplete for 23 of the 93 children deemed eligible to enter the study. There was no significant preponderance of these 23 children among the four treatment groups (table 2). There was a significant decrease in temperature at three hours for all four doses of ibuprofen (p<001) with the largest decrease for the highest dose of ibuprofen (table 3). The mean axillary temperatures of the children in the four randomised groups at baseline and three hours after the first ibuprofen dose are shown in fig 1. Interpretation of the data after three hours is confounded by the supplementary doses given to some children resulting in children within one randomised group having received doses which overlap with another group. Analysis of covariance showed that the influence of dose on the magnitude of the body temperature reduction was significant (p=002), a higher dose of ibuprofen being associated with a lower axillary temperature three hours later. The mean temperature at three hours after the 0-625 mg/kg dose was significantly greater (p<0 01) than that for the 5 0 mg/kg dose and this was despite (fig 2) .
In order to assess the rate of axillary temperature reduction, mean axillary temperatures at intervals over the first three hours of the study are shown in figure 2 . In all but the 0-625 mg/kg ibuprofen group, there was a steady reduction in mean axillary temperature over the first three hours after the initial dose of ibuprofen. The mean axillary temperature of the 0-625 mg/kg group rose from 37-5°C at two hours to 378°C at three hours. The reduction in axillary temperature between two and three hours in the other three groups was only 0 1-0-20C. That is to say, in the three higher dose groups most of the temperature reduction achieved by three hours (fig 1) had already occurred by two hours.
SUPPLEMENTARY DOSE OF IBUPROFEN
A total of 39 out of the 93 children warranted the 'rescue' dose at three hours after the initial, randomised dose and these children were not evenly distributed between the four randomisation groups (table 4). The higher the initial dose of ibuprofen, the more likely the children were to have an axillary temperature below 37-2°C at three hours. The proportions receiving a 'rescue' dose at three hours were 68%, 47% 42%, and 23% for the 0625, 1-25, 2-5, and 5 0 mg/kg ibuprofen groups respectively. These represent significant differences (p=0 03).
CLINICAL SCORE
Although there appears to be a trend with lower doses resulting in less clinical improvement, the differences between the scores at three hours did not reach significance (table 5) . Interpretation of the data after three hours is confounded by the supplementary medication given to some children.
ACCEPTABILITY OF THE MEDICATION
There were no significant differences in the acceptability of medications containing diffe- Figure 2 Reduction ofaxillary temperature (°C) ofchild doses. To determine the minimum effective dose requires criteria to be set that define efficacy. Clearly time has to be included in any definition. An agent that works too slowly will not be clinically useful while a drug that works quickly but then fails to prevent the pyrogen, or the body's physiological response to a falling body temperature, raising body temperature again almost immediately is also unsatisfactory. It was therefore decided to adopt for the study protocol a reduction of 1°C or more in axiliary temperature at three hours as the principal measure of antipyretic efficacy. In the 5 mg/kg dose group, 82% of the children achieved a temperature reduction of at least this size (fig 3) .
In a study directly comparing a 5 mg/kg/dose of ibuprofen and a 10 mg/kg/dose of paracetamol in febrile children, it was shown that both were superior to placebo and that 5 ing fever control than 10 mg/kg paracetamol.8 However, doses of 15 mg/kg paracetamol are commonly prescribed.
Although 39 children warranted 'rescue' treatment, only five of these children had received an initial 5 mg/kg dose of ibuprofen. The 'rescue' medication was given if the child's axillary temperature remained above 372°C three hours after the initial randomised dose and the apparent 'failure' of the 5 mg/kg dose in these five children must be viewed against this very strict temperature criterion and in comparison with other antipyretic measures. The mean baseline axillary temperature was 39°C in the 5 mg/kg ibuprofen group of our study. In an earlier study in which children had a mean baseline oral temperature of 39°C, the mean oral temperature three hours later remained at 38-7°C if only nursing measures were used and was 37T8°C if 10 mg/kg paracetamol had been given.
Finally, the 5 mg/kg ibuprofen dose did not compare unfavourably in our study with the weaker doses in acceptability or in the nature of adverse events.
